Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn's disease and ulcerative colitis. - D'Haens, Geert; Danese, Silvio; Panaccione, Remo; Rubin, David T; Peyrin-Biroulet, Laurent; Matsuoka, Katsuyoshi; Loftus, Edward V; Kobayashi, Taku; Elsharkawi, Walid; Miceli, Rosa; Ahmed, Samia; Luo, Yi; et al. (Journal of Crohn's & Colitis, 2025)